Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia


B-cell Childhood Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

What is the purpose of this trial?

This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.

Participation Guidelines

1 Year - 30 Years

Click here for detailed information about who can participate in this trial.

Children's Oncology Group
National Cancer Institute (NCI)
August 2010
Last Updated:
February 17, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01190930